Literature DB >> 7522251

Monocyte chemotactic protein-2, monocyte chemotactic protein-3, and fibroblast-induced cytokine. Three new chemokines induce chemotaxis and activation of basophils.

R Alam1, P Forsythe, S Stafford, J Heinrich, R Bravo, P Proost, J Van Damme.   

Abstract

Cytokine-dependent mediator release from basophils and mast cells may play an important role in the pathogenesis of allergic and inflammatory conditions. Many C-C chemokines have been found to activate basophils and mast cells. We investigated the effect of three newly identified C-C chemokines, monocyte chemotactic protein-2 and -3 (MCP-2, MCP-3) and fibroblast-induced cytokine (FIC) on basophils and mast cells. We found that all three cytokines induced histamine secretion from basophils in a dose-dependent manner. The secretion of histamine was a Ca(2+)-dependent process. MCP-3 was the most potent activator of basophils. MCP-3 and FIC activated basophils from all study subjects, whereas the histamine release by MCP-2 was donor-dependent. The histamine-releasing activity of MCP-2, MCP-3, and FIC was compared with that of MCP-1, RANTES, and macrophage inflammatory protein-1 alpha using basophils from 10 donors. MCP-1 was the most potent among all the C-C chemokines. However, MCP-3 was nearly as potent. MCP-2, MCP-3, and FIC induced significant chemotaxis of basophils. None of the cytokines activated mouse peritoneal mast cells. The synthesis of mRNA for MCP-3 was investigated by reverse-transcription PCR using allergen-stimulated PBMC and bronchoalveolar lavage cells. Both MNC and bronchoalveolar lavage cells expressed mRNA for MCP-3. The results of this study indicate that MCP-2, MCP-3, and FIC are novel histamine-releasing factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522251

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1, -2, -3 and -4.

Authors:  J H Wain; J A Kirby; S Ali
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Chemokines and chemokine receptors: their role in allergic airway disease.

Authors:  M E Rothenberg; N Zimmermann; A Mishra; E Brandt; L A Birkenberger; S P Hogan; P S Foster
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

3.  Association of serum cytokines with colorectal polyp number and type in adult males.

Authors:  Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  Eur J Cancer Prev       Date:  2016-05       Impact factor: 2.497

4.  Porphyromonas gingivalis lipopolysaccharide is poorly recognized by molecular components of innate host defense in a mouse model of early inflammation.

Authors:  R A Reife; R A Shapiro; B A Bamber; K K Berry; G E Mick; R P Darveau
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

5.  Progress and challenges in the understanding of chronic urticaria.

Authors:  Marta Ferrer; Allen P Kaplan
Journal:  Allergy Asthma Clin Immunol       Date:  2007-03-15       Impact factor: 3.406

6.  Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis.

Authors:  Chuan-Hui Kuo; Andrea M Collins; Douglas R Boettner; YanFen Yang; Santa J Ono
Journal:  J Immunol       Date:  2016-12-12       Impact factor: 5.422

7.  Plasma proteome profiles associated with inflammation, angiogenesis, and cancer.

Authors:  Karen S Kelly-Spratt; Sharon J Pitteri; Kay E Gurley; Denny Liggitt; Alice Chin; Jacob Kennedy; Chee-Hong Wong; Qing Zhang; Tina Busald Buson; Hong Wang; Samir M Hanash; Christopher J Kemp
Journal:  PLoS One       Date:  2011-05-12       Impact factor: 3.240

8.  Blood histamine levels (BHL) in infants and children with respiratory and non-respiratory diseases.

Authors:  C Ponvert; L Galoppin; J Paupe; J de Blic; M Le Bourgeois; P Scheinmann
Journal:  Mediators Inflamm       Date:  2001-02       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.